US7838012B2ExpiredUtilityA1
S. aureus fibrinogen binding protein gene
Est. expiryAug 22, 2014(expired)· nominal 20-yr term from priority
C07K 16/1271C07K 14/31C07K 2317/76
90
PatentIndex Score
9
Cited by
1
References
2
Claims
Abstract
The isolation of genes and proteins from Staphylococcus aureus is provided, and the nucleic acids coding for specific regions of the S. aureus protein are described. The nucleic acids encode proteins that can be useful as vaccines or in pharmaceutical compositions for application to prevent infection, promotion of wound healing, blocking adherence to indwelling medical devices, or diagnosis of infection.
Claims
exact text as granted — not AI-modified1. A method of immunizing a mammal comprising administering to said mammal an immunogenic amount of an amino acid sequence selected from the group consisting of SEQ ID NO: 2, amino acids 23 to 550 of SEQ ID NO:2, 143 to 550 of SEQ ID NO:2, 219 to 550 of SEQ ID NO:2, 332 to 550 of SEQ ID NO:2, 420 to 550 of SEQ ID NO:2, 546 to 933 of SEQ ID NO:2, 332 to 425 of SEQ ID NO: 2, 23 to 424 of SEQ ID NO:2, 23 to 308 of SEQ ID NO:2, 40 to 559 of SEQ ID NO:2 and 221 to 550 of SEQ ID NO:2.
2. A method of raising an immune response against S. aureus in a human or animal patient comprising administering to said patient a composition comprising an immunogenic amount of an amino acid sequence selected from the group consisting of SEQ ID NO: 2, amino acids 23 to 550 of SEQ ID NO:2, 143 to 550 of SEQ ID NO:2, 219 to 550 of SEQ ID NO:2, 332 to 550 of SEQ ID NO:2, 420 to 550 of SEQ ID NO:2, 546 to 933 of SEQ ID NO:2, 332 to 425 of SEQ ID NO: 2, 23 to 424 of SEQ ID NO:2, 23 to 308 of SEQ ID NO:2, 40 to 559 of SEQ ID NO:2 and 221 to 550 of SEQ ID NO:2, and a pharmaceutically acceptable carrier or adjuvant.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.